N/A N=58 Functional Monitoring for Motor Pathway in Brain Tumor Surgery Within Eloquent Area
Glioma, Motor Pathway
Primary: Extent of Tumor Resection — 40; 7; 7; 4 participants
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
N/A N=11 Measuring Fatty Acid Oxidation in Gliomas Using 18F-FPIA PET/MRI
Glioma
Primary: Quantitative Measurement of [18F]-FPIA Uptake in Human Gliomas — 0.9041; 1.3529; 2.0470 SUV60_max
Phase 1 N=3 Neural Stem Cell Based Virotherapy of Newly Diagnosed Malignant Glioma
Glioma · Anaplastic Astrocytoma · Anaplastic Oligodendroglioma
Primary: Percentage of Dose-limiting Toxicities — 0; 0; 17 Percentage of dose-limiting toxicities
Phase 2 N=30 Spectroscopic MRI-Guided Radiation Therapy Planning in Glioblastoma
Glioblastoma · Gliosarcoma
Primary: Feasibility as Assessed by Successful Co-registration of sMRI-based Treatment Volumes With Clinical Images Into the Radiation Treatment Execution Platform — 30…
Phase 2 N=120 Temozolomide in Treating Patients With Low-Grade Glioma
CNS Tumor, Adult
Primary: Response Rate (Complete and Partial Response) — 7 Participants
N/A N=11 Image-Guided Stereotactic Biopsy of High Grade Gliomas
Brain Cancer · Glioma
Primary: Invest Relation Btw Voxel-based Determ of Prolif Rate & Obser MR Imaging Featu (i.e., Ktrans or Microvas Permeabil; fBV, Tiss Fract Blood Vol), as Well With Spatially…
Phase 2 N=136 Temozolomide and Radiation Therapy in Treating Patients With Gliomas
Brain and Central Nervous System Tumors
Primary: Overall Survival Rate at 3 Years — 73.1 percentage of participants — p=<0.001
N/A N=58 Comparative Study of Intraoperative MRI-guided vs. Conventional Glioma Surgery
Glioma
Primary: Extent of Resection — 24; 25 participants
Phase 2 N=92 Radiation Therapy in Treating Young Patients With Gliomas
Brain Tumor · Central Nervous System Tumor
Primary: Marginal-failure Rate — 0 percentage of failure rate
Phase 2 N=72 Gliadel Wafer and Fluorescence-Guided Surgery With 5-ALA Followed by Radiation Therapy And Temozolomide in Treating Patients With Primary Glioblastoma
Glioblastoma
Primary: Safety, Tolerability, and Feasibility of Combination Intra-operative 5-ALA and Gliadel Wafers Prior to Adjuvant Radiotherapy Plus Temozolomide — 62; 9; 6; 45 Participants
Phase 2 N=5 Vaccine for Patients With Newly Diagnosed or Recurrent Low-Grade Glioma
Adult Diffuse Astrocytoma · Adult Mixed Glioma · Adult Oligodendroglioma
Primary: Progression-free Survival (PFS) of Low Grade Glioma Patients Treated With Autologous Dendritic Cells Pulsed With Autologous Tumor Lysate — 0; 1; 1; 1 participants
Phase 1 N=16 Genetically Modified Neural Stem Cells, Flucytosine, and Leucovorin for Treating Patients With Recurrent High-Grade Gliomas
Adult Anaplastic Astrocytoma · Adult Anaplastic Oligodendroglioma · Adult Giant Cell Glioblastoma
Primary: Number of Participants With Dose Limiting Toxicities (DLTs) and Maximum Tolerated Dose (MTD) — 0; 0; 0; 1 Participants
N/A N=64 Cortical Contributions to Motor Sequence Learning
Brain Injuries
Primary: Serial Reaction Time Task (SRTT) Performance — 31; 35; 38; 24 milliseconds (ms)
Phase 2 N=121 Lerapolturev in Recurrent Malignant Glioma
Malignant Glioma
Primary: Number of Participants With Objective Radiographic Response — 5; 2 Participants
Phase 2 N=90 Glioblastoma Multiforme (GBM) Proton vs. Intensity Modulated Radiotherapy (IMRT)
Brain Cancer
Primary: Time to Cognitive Failure — 7.7; 4.9 months — p=.74
Phase 2 N=60 Temozolomide in Treating Patients With Recurrent High-Grade Glioma
Recurrent Central Nervous System Neoplasm
Primary: 6 Month Progression-free Survival — 10; 50 percentage of patients
Phase 2 N=20 Autologous CMV-Specific Cytotoxic T Cells and Temozolomide in Treating Patients With Glioblastoma
Cytomegalovirus Positive · Glioblastoma · Gliosarcoma
Primary: Maximum Tolerated Dose (MTD) (Recurrent Glioblastoma Participant Cohort)- Phase I — 3; 3; 3; 7 participants
Phase 2 N=151 A Study in Subjects With Recurrent Malignant Glioma
Glioma
Primary: Progression Free Survival (PFS) Rate at Month 6 — 11.0; 21.2; 8.0; 7.6 Percentage of participants
Phase 2 N=12 Antineoplaston Therapy in Treating Children With Visual Pathway Glioma
Visual Pathway Glioma
Primary: Number of Participants With Objective Response — 2; 2; 3; 1 Participants
Phase 3 N=108 Gleolan for Visualization of Newly Diagnosed or Recurrent Meningioma
Meningioma
Primary: The Percentage of Participants Who Had at Least 1 Indeterminate Tissue or Unexpected Fluorescent End of Surgery (EOS) Tissue Where Gleolan-induced PpIX Fluorescence…
Phase 2 N=40 Low-dose Temozolomide for 2 Weeks on Brain Tumor Enzyme in Patients With Gliomas (P04602 AM1) (Completed)
Glioma
Primary: MethylGuanine-DNA MethylTransferase [MGMT] Activity Measured From the Tumor Tissue During Surgery — 333.7; 105.1 fmol/mg of proteins — p=0.09
Phase 4 N=8 Perampanel in Seizure Patients With Primary Glial Brain Tumors
Brain Tumor, Primary
Primary: Percentage of Patients With ≥50% Seizure Reduction During the Maintenance Period Compared With Seizure Frequency Before Initiation of Perampanel
N/A N=36 Sedatives' Effects on Neurological Function in Patients With Eloquent Area Glioma
Glioma
Primary: Task Completing Time Change Between Sedation and Baseline Measured by 9-hole Peg Test — 27.8; 19.1; 54.3; 21.4 seconds — p=<0.01
N/A N=42 Improving Motor Function After Spinal Cord Injury
Spinal Cord Injury
Primary: Physiology Measurements Before and After rTMS/Sham rTMS Protocol- Changes in Amplitude of Motor Evoked Potential (MEP) From TMS — 0.31; 0.43; 0.45; 0.65 millivolts (mV)
Phase 2 N=58 Everolimus in Treating Patients With Recurrent Low-Grade Glioma
Adult Diffuse Astrocytoma · Adult Mixed Glioma · Adult Oligodendroglioma
Primary: Progression-free Survival at 6 Months. — 39; 6 Participants
Phase 1 N=24 IDH1 Peptide Vaccine for Recurrent Grade II Glioma
Brain Cancer · Brain Neoplasm, Primary · Brain Neoplasms, Recurrent
Primary: Percentage of Participants With an Unacceptable Toxicity — 0 percentage of participants
N/A N=13 [18F] FACBC and [18F] FLT PET Imaging in Central Nervous System Tumors
Brain Cancer · Gliomas
Primary: Determine & Comp Biodistribution, Clearance, & Dosimetry of [18F]FACBC & [18F]FLT Tissue/Organs w/i the Field of View of the Dynamic PET Imag Studies prior-to & During…
Phase 2 N=31 Low Dose Radiation Therapy for Glioblastoma Multiforme
High Grade Glioma
Primary: Response Rate
Phase 2 N=7 Phase II Trial of Peginterferon Alpha-2b and Thalidomide in Adults With Recurrent Gliomas
Glioma
Primary: Progression-free Survival
Phase 3 N=35 Stereotactic Radiology Versus Chemotherapy for Recurrent/Progressive Glioblastoma After Second-Line Chemotherapy
Recurrent or Progressive Glioblastoma
Primary: Local Tumor Control — 14; 4 Participants